Showing results (21-30 of 372) with videos related to
Sort By:
Pageof 38
The Urologic Clinics of North America|October 23, 2012
Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptorYohann Loriot, Amina Zoubeidi, Martin E GleaveDrugs|May 5, 2022
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate CancerRonan Flippot, Anna Patrikidou, Mihaela Aldea, et al.European Urology|May 1, 2020
Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 PandemicLouis Lenfant, Thomas Seisen, Yohann Loriot, et al.Future Oncology (London, England)|November 2, 2023
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-upYohann Loriot, Anne O'Hagan, Arlene O Siefker-RadtkeExpert Review of Anticancer Therapy|August 28, 2015
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerKarim Fizazi, Laurence Albiges, Yohann Loriot, et al.Bulletin Du Cancer|May 6, 2014
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone]Emilie Boissier, Yohann Loriot, Stéphane Vignot, et al.La Revue Du Praticien|June 23, 2021
["Treatment of bladder cancer with immune checkpoints inhibitors"]Élisabeth Grobet-Jeandin, Ugo Pinar, Yohann Loriot, et al.Critical Reviews in Oncology/Hematology|November 22, 2015
Novel therapeutic targets in advanced urothelial carcinomaMathieu Rouanne, Yohann Loriot, Thierry Lebret, et al.Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.Pageof 38